ARTICLE | Company News
Evotec, Harvard deal
May 20, 2013 7:00 AM UTC
Evotec partnered with the university to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. Harvard will contribute undisclosed research and IP relating on proprietary assays, small molecule hits and x-ray crystallographic tools, while Evotec will contribute its drug discovery infrastructure and experience in the antibacterial space. Evotec will have rights to the antibacterials resulting from the deal. The partners declined to disclose details. ...